926 related articles for article (PubMed ID: 17430272)
21. Re: The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer.
Gardiner RA; Nicol DL; Green HJ; Yaxley J; Watson R; Mactaggart P; Headley BC; Swanson C; Pakenham KI
J Urol; 2004 Aug; 172(2):774; author reply 774-5. PubMed ID: 15247782
[No Abstract] [Full Text] [Related]
22. Bicalutamide: a new antiandrogen for use in combination with castration for patients with advanced prostate cancer.
Blackledge G; Kolvenbag G; Nash A
Anticancer Drugs; 1996 Jan; 7(1):27-34. PubMed ID: 8742095
[TBL] [Abstract][Full Text] [Related]
23. [Total androgen blockade].
Namiki M; Mizokami A
Nihon Rinsho; 2002 Dec; 60 Suppl 11():193-8. PubMed ID: 12599570
[No Abstract] [Full Text] [Related]
24. [First line therapy in the treatment of metastatic prostate cancer].
Sakai H; Kanetake H
Gan To Kagaku Ryoho; 2003 Jan; 30(1):43-9. PubMed ID: 12557704
[TBL] [Abstract][Full Text] [Related]
25. [Usefulness and positioning of MAB therapy for prostate cancer].
Akaza H; Chodak GW; Hirao Y
Gan To Kagaku Ryoho; 2005 Oct; 32(10):1507-20. PubMed ID: 16227758
[TBL] [Abstract][Full Text] [Related]
26. The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer.
Cherrier MM; Rose AL; Higano C
J Urol; 2003 Nov; 170(5):1808-11. PubMed ID: 14532781
[TBL] [Abstract][Full Text] [Related]
27. Prostate specific antigen (PSA) may be a poor marker for progression of prostate cancer after treatment with a combination of chemo-hormonal therapies.
Sartor O
J La State Med Soc; 2008; 160(2):99-100. PubMed ID: 18681353
[TBL] [Abstract][Full Text] [Related]
28. Changes in free and free-to-total prostate specific antigen after androgen deprivation or chemotherapy in patients with advanced prostate cancer.
Berruti A; Dogliotti L; Fasolis G; Mosca A; Tarabuzzi R; Torta M; Mari M; Fontana D; Angeli A
J Urol; 1999 Jan; 161(1):176-81. PubMed ID: 10037393
[TBL] [Abstract][Full Text] [Related]
29. Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails.
Kassouf W; Tanguay S; Aprikian AG
J Urol; 2003 May; 169(5):1742-4. PubMed ID: 12686822
[TBL] [Abstract][Full Text] [Related]
30. [Intermittent androgen deprivation treatment of prostate cancer restarted at low level of serum prostate specific antigen: a pilot study].
Maekawa S; Maegawa M; Ushida H; Inoue K; Kaneko Y; Ohmori K; Nishimura K
Hinyokika Kiyo; 2001 Aug; 47(8):553-5. PubMed ID: 11579594
[TBL] [Abstract][Full Text] [Related]
31. Is combined androgen blockade with bicalutamide cost-effective compared with combined androgen blockade with flutamide?
Ramsey S; Veenstra D; Clarke L; Gandhi S; Hirsch M; Penson D
Urology; 2005 Oct; 66(4):835-9. PubMed ID: 16230148
[TBL] [Abstract][Full Text] [Related]
32. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.
Sato N; Akakura K; Isaka S; Nakatsu H; Tanaka M; Ito H; Masai M;
Urology; 2004 Aug; 64(2):341-5. PubMed ID: 15302491
[TBL] [Abstract][Full Text] [Related]
33. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma.
Boccon-Gibod L; Fournier G; Bottet P; Marechal JM; Guiter J; Rischman P; Hubert J; Soret JY; Mangin P; Mallo C; Fraysse CE
Eur Urol; 1997; 32(4):391-5; discussion 395-6. PubMed ID: 9412794
[TBL] [Abstract][Full Text] [Related]
34. [Giant prostate carcinoma treated effectively with endocrine therapy: case report].
Masue N; Hasegawa Y
Hinyokika Kiyo; 2007 Feb; 53(2):133-5. PubMed ID: 17352166
[TBL] [Abstract][Full Text] [Related]
35. Residual prostate cancer in patients treated with endocrine therapy with or without radical radiotherapy: a side study of the SPCG-7 randomized trial.
Solberg A; Haugen OA; Viset T; Bergh A; Tasdemir I; Ahlgren G; Widmark A; Angelsen A
Int J Radiat Oncol Biol Phys; 2011 May; 80(1):55-61. PubMed ID: 20598453
[TBL] [Abstract][Full Text] [Related]
36. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
Morote J; Orsola A; Planas J; Trilla E; Raventós CX; Cecchini L; Catalán R
J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136
[TBL] [Abstract][Full Text] [Related]
37. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer.
Labrie F; Dupont A; Giguère M; Borsanyi JP; Lacourciere Y; Bélanger A; Lachance R; Emond J; Monfette G
Prog Clin Biol Res; 1988; 260():41-62. PubMed ID: 3283766
[TBL] [Abstract][Full Text] [Related]
38. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of Immediate Switching from Bicalutamide to Flutamide as Second-Line Combined Androgen Blockade.
Yokomizo Y; Kawahara T; Miyoshi Y; Otani M; Yamanaka S; Teranishi J; Noguchi K; Yao M; Uemura H
Biomed Res Int; 2016; 2016():4083183. PubMed ID: 27493956
[TBL] [Abstract][Full Text] [Related]
40. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease.
Scher HI; Liebertz C; Kelly WK; Mazumdar M; Brett C; Schwartz L; Kolvenbag G; Shapiro L; Schwartz M
J Clin Oncol; 1997 Aug; 15(8):2928-38. PubMed ID: 9256137
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
